Physician profile

Stuart S Kaplan

Neurological Surgery · Las Vegas, NV

NPI 1508823824

$6,847.08

in general payments reported to CMS, 2019-2025

35 companies · $832 in 2025

The $832 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,069.61
Education$39.52

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Corelink, LLC $2,141.03 2022
Abbott Laboratories $1,260.07 2019-2025 Proclaim, Penta, Eterna
Medtronic USA, INC. $595.99 2019-2020
Providence Medical Technology, INC. $479.72 2021-2025
Boston Scientific Corporation $327.81 2019-2025 General - Pain Management, Artisan
Stryker Corporation $274.60 2019-2020
Nuvasive, INC. $267.94 2019-2020
Medtronic, INC. $258.95 2021-2025 Inceptiv, Strata, Kyphon Express II Kyphopak Tray
Nevro Corp. $229.13 2019-2024 Senza
Saluda Medical Americas, INC. $137.24 2024 Evoke
Si-Bone, INC. $93.23 2019-2025
Gt Medical Technologies, INC $72.45 2025 Gammatile
Orthofix Medical, INC. $63.20 2023-2025 Physio-Stim
Arbor Pharmaceuticals, INC. $58.62 2019-2020
Arteriocyte Medical Systems, INC. $57.13 2022
Show all 34 companies
CompanyGeneral paymentsYearsTop products
Radius Health, INC. $46.76 2021-2022
Smith+Nephew, INC. $43.93 2025 Pico
Astrazeneca Pharmaceuticals LP $39.52 2024
Biocomposites INC $37.25 2024-2025 Stimulan
Alexion Pharmaceuticals, INC. $35.89 2021-2025 Strensiq
Depuy Synthes Sales INC. $34.31 2020
Globus Medical, INC. $33.61 2025 Vyrsa V1
Integra Lifesciences Corporation $30.02 2019
Acera Surgical, INC. $29.22 2024 Restrata Wound Matrix
Solventum Corporation $26.17 2024 Prevena, Bair Hugger, V.A.C. Veraflo
Kls-Martin L.P. $24.09 2024
Forte Bio-Pharma LLC $23.22 2021
Monteris Medical Corporation $22.49 2019
Livanova USA, INC. $21.73 2021
Portola Pharmaceuticals, LLC $18.74 2019
Expanding Innovations, INC. $17.91 2025 X-Pac
Pacira Pharmaceuticals Incorporated $16.43 2020
Zimmer Biomet Holdings, INC. $14.69 2020
Stimwave Technologies Incorporated $13.99 2021

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$22,200.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stuart S Kaplan

$6,847.08

in general payments reported 2019-2025

Years
2019-2025
Top company
Surgalign Spine Technologies, INC.
Context
The $832 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).

https://glasscript.com/doctor/804517/stuart-s-kaplan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.